Connor Clark & Lunn Investment Management Ltd. Purchases 181,075 Shares of Zoetis Inc. $ZTS

Connor Clark & Lunn Investment Management Ltd. raised its position in shares of Zoetis Inc. (NYSE:ZTS) by 96.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 368,950 shares of the company’s stock after buying an additional 181,075 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned about 0.08% of Zoetis worth $53,985,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of ZTS. Beese Fulmer Investment Management Inc. boosted its stake in Zoetis by 2.4% in the third quarter. Beese Fulmer Investment Management Inc. now owns 3,672 shares of the company’s stock worth $537,000 after purchasing an additional 85 shares in the last quarter. RiverPark Advisors LLC increased its stake in shares of Zoetis by 0.9% in the third quarter. RiverPark Advisors LLC now owns 13,514 shares of the company’s stock valued at $1,977,000 after buying an additional 116 shares in the last quarter. Riverpark Capital Management LLC raised its holdings in shares of Zoetis by 10.0% in the third quarter. Riverpark Capital Management LLC now owns 5,313 shares of the company’s stock valued at $777,000 after buying an additional 485 shares during the last quarter. Franklin Resources Inc. raised its holdings in shares of Zoetis by 144.2% in the third quarter. Franklin Resources Inc. now owns 332,760 shares of the company’s stock valued at $48,689,000 after buying an additional 196,504 shares during the last quarter. Finally, Magnetar Financial LLC lifted its position in Zoetis by 108.0% during the 3rd quarter. Magnetar Financial LLC now owns 7,123 shares of the company’s stock worth $1,042,000 after buying an additional 3,698 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have weighed in on ZTS. Stifel Nicolaus lowered their price objective on shares of Zoetis from $140.00 to $130.00 and set a “hold” rating for the company in a research report on Tuesday, November 18th. Piper Sandler reiterated a “neutral” rating and set a $135.00 target price (down from $190.00) on shares of Zoetis in a research report on Thursday, January 22nd. Barclays started coverage on shares of Zoetis in a research note on Monday, December 8th. They set an “equal weight” rating and a $136.00 price target on the stock. Morgan Stanley set a $160.00 price objective on shares of Zoetis in a research report on Thursday, December 18th. Finally, KeyCorp began coverage on Zoetis in a research report on Thursday, November 20th. They issued a “sector weight” rating on the stock. Six investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $152.91.

Zoetis Stock Performance

Zoetis stock opened at $119.82 on Thursday. The company has a market cap of $50.58 billion, a PE ratio of 19.90, a PEG ratio of 1.84 and a beta of 0.95. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71. Zoetis Inc. has a 1 year low of $115.25 and a 1 year high of $172.23. The company’s 50-day moving average is $125.75 and its two-hundred day moving average is $132.31.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, February 12th. The company reported $1.48 EPS for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The company had revenue of $2.39 billion during the quarter, compared to analysts’ expectations of $2.36 billion. During the same quarter in the previous year, the company earned $1.40 EPS. Zoetis’s revenue was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Equities analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be paid a $0.53 dividend. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.8%. Zoetis’s dividend payout ratio is 35.22%.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.